spd
mannosebind
lectin
base
motif
found
serum
collectin
construct
mutant
version
human
spd
ncrd
increas
antivir
activ
mutant
ncrd
also
potenti
activ
crosslink
f
ab
fragment
protein
complex
henc
antivir
activ
ncrd
increas
distinct
complementari
strategi
name
crosslink
ncrd
variou
mean
mutagenesi
crd
residu
increas
viral
bind
find
may
relev
antivir
therapi
n
terminu
extens
studi
spd
shown
level
oligomer
import
impact
antivir
activ
spd
commonli
form
dodecam
trimer
togeth
make
crosslik
structur
human
spd
also
present
vivo
vitro
fulllength
trimer
highmolecular
weight
multim
trimer
per
molecul
dodecam
multim
greater
antivir
activ
trimer
neck
domain
collectin
mediat
trimer
recombin
prepar
contain
neck
crd
ncrd
collectin
spontan
trimer
lectin
activ
ncrd
prepar
human
spd
hncrd
explor
therapeut
rel
easi
produc
bacteria
benefici
activ
variou
vitro
murin
model
system
instanc
hncrd
restor
function
spdmice
amelior
respiratori
synciti
viru
infect
pulmonari
hypersensit
reaction
note
mani
studi
employ
ncrd
construct
also
contain
short
ntermin
collagen
domain
fragment
impact
activ
explor
activ
human
spd
ncrd
regard
iav
use
ncrd
without
collagen
sequenc
protein
bind
site
tag
n
terminu
unfortun
human
spd
ncrd
trimer
minim
abil
bind
iav
greatli
reduc
antivir
activ
compar
fulllength
spd
shown
howev
crosslink
hncrd
certain
monoclon
antibodi
mab
direct
spd
result
strong
antivir
activ
addit
mutat
introduc
around
lectin
site
crd
confer
antivir
activ
hncrd
without
need
crosslink
goal
current
project
understand
mechan
mab
enhanc
antivir
activ
ncrd
firstli
want
determin
fc
domain
mab
need
enhanc
specif
function
activ
ncrd
end
evalu
effect
fab
fragment
enhanc
mab
combin
wildtyp
spd
ncrd
also
want
develop
altern
method
crosslink
ncrd
could
directli
compar
activ
ncrd
variou
collectin
crosslink
confirm
increas
intrins
antivir
activ
ncrd
serum
collectin
achiev
use
multival
prepar
protein
panel
collectin
ncrd
contain
protein
bind
site
way
establish
hierarchi
antivir
activ
among
wildtyp
collectin
ncrd
follow
conglutinin
mannos
bindinglectin
mbl
spd
final
want
determin
mutant
version
human
spd
ncrd
increas
antivir
activ
would
show
increas
activ
crosslink
particular
serum
collectin
hydrophob
amino
acid
valin
isoleucin
posit
use
spd
number
wherea
spd
surfact
protein
arginin
lysin
rodent
spd
site
human
spd
ncrd
contain
substitut
increas
antivir
activ
compar
ncrd
wildtyp
spd
show
crosslink
mutant
either
mab
protein
complex
caus
mark
increas
antivir
activ
note
antivir
activ
crosslink
protein
complex
exceed
wildtyp
collectin
ncrd
treat
similar
manner
iav
grown
chorioallanto
fluid
chicken
egg
purifi
discontinu
sucros
gradient
previous
describ
viru
dialyz
pb
remov
sucros
aliquot
store
c
need
philippin
bovin
serum
inhibitor
resist
variant
kindli
provid
dr
e
margot
ander
univers
melbourn
melbourn
australia
thaw
viral
stock
contain
approxim
plaqueform
unitsml
strain
rel
resist
collectin
lectin
affin
mannos
like
cyanovirin
dodecam
wildtyp
recombin
human
spd
use
control
prepar
express
cho
cell
purifi
describ
elsewher
ncrd
prepar
includ
wildtyp
human
ncrd
hncrd
rat
ncrd
rncrd
ncrd
mbl
conglutinin
mutant
produc
e
coli
describ
elsewher
use
bacteri
express
protein
feasibl
known
posttransl
modif
within
human
spd
crd
neck
domain
selfassembl
vitro
stabl
trimer
lectin
activ
ncrd
prepar
contain
protein
bind
site
n
terminu
describ
previous
sequenc
verifi
autom
sequenc
entir
code
sequenc
fusion
protein
rosettablu
compet
cell
transform
wildtyp
mutant
construct
vector
express
protein
isol
inclus
bodi
refold
oligomer
fusion
protein
purifi
nickel
affin
chromatographi
trimer
isol
gel
filtrat
chromatographi
system
protein
isol
similar
yield
similarli
low
level
endotoxin
approxim
euml
limulu
lysat
assay
cambrex
walkersvil
md
usa
fusion
protein
show
expect
mobil
sdspage
absenc
presenc
sulfhydryl
reduct
previous
demonstr
wildtyp
protein
mutant
use
current
studi
form
trimer
like
wildtyp
spd
ncrd
differ
singl
note
amino
acid
substitut
produc
sitedirect
mutagenesi
perform
use
quikchang
ii
xl
sitedirect
mutagenenesi
kit
stratagen
la
jolla
calif
usa
human
spd
neck
crd
dna
templat
monoclon
antibodi
mab
rais
spd
inocul
mice
gml
human
spd
previous
describ
mab
bind
ncrd
human
spd
although
neither
block
bind
spd
mannan
iav
fab
fraction
hyb
obtain
proteolysi
whole
immunoglobulin
papain
sigmaaldrich
denmark
antibodi
dialyz
naoac
ph
edta
papain
antibodi
mix
togeth
ratio
weight
antibodi
mg
papain
g
dissolv
ml
naoac
ph
contain
edta
cystein
solut
incub
c
h
degre
format
fab
fragment
monitor
sdspage
size
select
use
superdex
column
ge
healthcar
denmark
f
ab
fragment
prepar
use
pepsin
follow
firstli
mg
purifi
hyb
batch
digest
pepsin
initi
buffer
exchang
mm
acet
buffer
ph
use
hitrap
fast
desalt
column
ww
pepsin
sigmaaldrich
ad
immunoglobulin
solut
igg
incub
overnight
c
fragment
elut
tb
ph
nan
size
fraction
superdex
column
pepsin
cleavag
yield
f
ab
fragment
appar
molecular
weight
kda
judg
sdspage
hemagglutin
ha
inhibit
measur
serial
dilut
collectin
host
defens
protein
prepar
roundbottom
plate
seroclust
uvinyl
plate
costar
cambridg
mass
usa
use
pb
contain
calcium
magnesium
diluent
ad
l
iav
give
final
concentr
ha
unitsml
ha
unitswel
iavprotein
mixtur
incub
min
room
temperatur
follow
addit
l
type
human
erythrocyt
suspens
minimum
concentr
protein
requir
fulli
inhibit
hemagglutin
activ
viral
suspens
determin
note
highest
dilut
protein
still
inhibit
ha
inhibit
ha
activ
given
well
demonstr
absenc
format
erythrocyt
pellet
inhibit
ha
activ
observ
highest
protein
concentr
use
valu
express
greater
maxim
protein
concentr
experi
ncrd
first
preincub
protein
proteinbiotin
proteinhorseradish
peroxidas
hrp
conjug
protein
prepar
purchas
novagen
viral
aggreg
measur
assess
light
transmiss
stir
suspens
iav
previous
describ
addit
viral
aggreg
visual
use
electron
microscopi
describ
elsewher
bind
trimer
ncrd
fusion
protein
iav
measur
previous
describ
use
proteinhrp
conjug
brief
elisa
plate
coat
viru
follow
wash
addit
ncrd
alon
ncrd
preincub
proteinhrp
wash
proteinhrp
ad
well
receiv
ncrd
bind
detect
use
peroxidas
substrat
pierc
rockford
ill
usa
valu
given
mean
standard
error
mean
sem
least
independ
experi
mdck
cell
monolay
prepar
plate
grown
confluenc
layer
infect
dilut
iav
prepar
min
c
pb
test
presenc
iavinfect
cell
h
use
mab
direct
influenza
viral
nucleoprotein
provid
dr
nanci
cox
cdc
atlanta
ga
usa
previous
describ
iav
preincub
min
c
spd
control
buffer
follow
addit
viral
sampl
mdck
cell
indic
spd
first
incub
mab
prior
ad
iav
neutrophil
healthi
volunt
isol
puriti
use
dextran
precipit
follow
ficollpaqu
gradient
separ
remov
mononuclear
cell
hypoton
lysi
elimin
contamin
erythrocyt
previous
describ
cell
viabil
determin
trypan
blue
stain
isol
neutrophil
resuspend
appropri
concentr
control
buffer
pb
use
within
h
neutrophil
collect
perform
inform
consent
approv
institut
review
board
boston
univers
school
medicin
raw
cell
obtain
american
type
cultur
collect
manassa
va
usa
fluorescein
isothiocyan
fitc
label
iav
strain
prepar
uptak
viru
neutrophil
measur
flow
cytometri
describ
elsewher
brief
iav
incub
neutrophil
min
c
presenc
control
buffer
trypan
blue
mgml
ad
sampl
quench
extracellular
fluoresc
follow
wash
neutrophil
fix
paraformaldehyd
neutrophilassoci
fluoresc
measur
use
flow
cytometri
mean
neutrophil
fluoresc
cell
count
per
sampl
measur
h
product
measur
assess
reduct
scopoletin
fluoresc
previous
describ
measur
made
use
polarstar
optima
fluoresc
plate
reader
bmg
labtech
durham
nc
usa
use
assay
decreas
fluoresc
occur
product
h
statist
comparison
made
use
student
pair
twotail
test
anova
post
hoc
test
tukey
anova
use
multipl
comparison
singl
control
shown
figur
mab
f
ab
fragment
nearli
equival
abil
increas
ha
inhibit
viral
neutral
activ
wildtyp
hncrd
indic
fc
domain
mab
need
activ
contrast
f
ab
fragment
mab
without
activ
indic
bival
crosslink
abil
mab
crucial
increas
antivir
activ
uptak
iav
shown
figur
f
ab
f
ab
fragment
mab
significantli
increas
uptak
iav
neutrophil
raw
cell
case
neutrophil
intact
antibodi
greater
effect
uptak
f
ab
fragment
suggest
fc
domain
may
engag
neutrophil
receptor
promot
viral
uptak
greater
extent
f
ab
fragment
alon
case
raw
cell
differ
effect
f
ab
fragment
intact
antibodi
previous
report
treatment
iav
hncrd
crosslink
mab
markedli
increas
neutrophil
h
respons
viru
shown
figur
c
addit
f
ab
hncrd
significantli
potenti
neutrophil
h
respons
elicit
iav
plu
hncrd
note
scopoletin
assay
h
gener
involv
quench
scopoletin
fluoresc
h
increas
h
gener
reflect
decreas
fluoresc
want
develop
addit
mean
crosslink
ncrd
confirm
find
obtain
f
ab
fragment
abl
compar
activ
variou
mammalian
ncrd
bind
mab
di
aliquot
strain
iav
preincub
ncrd
alon
ncrd
combin
intact
antibodi
spd
f
ab
f
ab
fragment
antibodi
effect
treatment
viral
ha
activ
viral
infect
mdck
cell
b
test
result
mean
sem
experi
ncrd
alon
concentr
gml
caus
inhibit
ha
activ
addit
f
ab
fragment
alter
result
howev
addit
intact
mab
f
ab
fragment
mab
result
ha
inhibit
p
b
similarli
ncrd
alon
gml
combin
f
ab
fragment
viral
neutral
activ
wherea
intact
mab
f
ab
fragment
caus
signific
inhibit
significantli
less
control
ncrd
alon
assess
anova
mab
alon
effect
viral
infect
black
bar
control
rect
human
spd
ncrd
contain
protein
bind
site
exploit
purpos
protein
conjug
hrp
use
detect
bind
ncrd
variou
ligand
previou
bind
studi
shown
differ
ncrd
prepar
equival
detect
proteinhrp
conjug
shown
figur
proteinhrp
present
highmolecular
weight
aggreg
nonreduc
sdspage
gel
wherea
free
protein
protein
conjug
biotin
exist
monom
properti
proteinhrp
exploit
studi
gener
aggreg
ncrd
contain
protein
bind
site
shown
figur
b
preincub
hncrd
proteinhrp
complex
result
substanti
increas
bind
iav
compar
situat
hncrd
ad
viru
follow
addit
proteinhrp
impli
proteinhrp
form
complex
hncrd
abl
bind
avidli
iav
present
multipl
hncrd
trimer
head
simultan
resembl
spd
multim
preincub
either
hncrd
rncrd
proteinhrp
also
allow
ncrd
inhibit
viral
ha
activ
fig
preincub
free
protein
proteinbiotin
confer
hainhibit
activ
prepar
provid
use
control
demonstr
fig
multimer
complex
protein
result
indic
multival
requir
protein
potenti
antivir
activ
ncrd
proteinhrp
conjug
also
abl
potenti
viral
neutral
activ
hncrd
fig
b
confer
viral
aggreg
activ
hncrd
fig
allow
hncrd
increas
neutrophil
raw
cell
uptak
iav
fig
b
suggest
increas
phagocyt
uptak
iav
occur
absenc
ntermin
domain
collectin
fc
domain
antibodi
long
viral
aggreg
occur
note
viral
aggreg
measur
assess
light
transmiss
stir
suspens
iav
assay
viral
aggreg
reduc
light
transmiss
compar
untreat
viru
sampl
treat
manner
figur
except
proteinhrp
free
protein
proteinbiotin
incub
hncrd
instead
antibodi
fragment
proteinhrp
enabl
hncrd
significantli
reduc
viral
ha
activ
viral
infect
b
p
n
experi
free
protein
proteinbiotin
enhanc
hainhibit
activ
hncrd
similar
result
obtain
use
rat
spd
ncrd
concentr
hncrd
use
b
gml
phagocyt
uptak
assay
analyz
electron
microscopi
show
clear
viral
aggreg
fig
c
proteinhrp
alon
absenc
ncrd
inhibit
ha
activ
viral
infect
data
shown
induc
viral
aggreg
fig
proteinhrp
alon
alter
viral
uptak
phagocyt
result
viral
aggreg
activ
data
shown
figur
compar
hainhibitori
activ
sever
wildtyp
collectin
ncrd
mutant
form
human
spd
ncrd
note
report
mutant
form
human
ncrd
substanti
increas
antivir
activ
com
similarli
addit
proteinhrp
ncrd
gml
result
signific
increas
viral
uptak
neutrophil
raw
cell
compar
hncrd
alon
n
neutrophil
n
raw
cell
proteinhrp
alon
alter
viral
uptak
data
shown
pmn
polymorphonuclear
cell
neutrophil
c
repres
electron
microscop
pictur
iav
treat
hncrd
alon
hncrd
proteinhrp
manner
viral
uptak
assay
pare
wildtyp
hncrd
wildtyp
ncrd
measur
activ
absenc
crosslink
previous
report
bovin
conglutinin
note
consider
greater
activ
wildtyp
collectin
ncrd
ncrd
contain
equival
protein
bind
site
hainhibitori
activ
protein
significantli
increas
proteinhrp
crosslink
proteinhrp
follow
hierarchi
activ
determin
conglutinin
mbl
human
spd
rat
spd
ncrd
intrins
activ
prior
crosslink
greatest
activ
crosslink
free
protein
proteinbiotin
increas
hainhibit
activ
data
shown
given
proteinhrp
caus
mark
increas
hainhibit
activ
test
abil
mab
increas
variou
antivir
activ
alon
lower
antivir
activ
significantli
greater
wildtyp
hncrd
prior
studi
incub
either
mab
increas
bind
iav
fig
antibodi
also
significantli
increas
hainhibit
activ
fig
b
effect
reproduc
use
f
ab
fragment
mab
fig
c
contrast
f
ab
fragment
significantli
reduc
intrins
hainhibit
activ
fig
c
similarli
full
mab
significantli
increas
neutral
activ
fig
wherea
f
ab
fragment
antibodi
essenti
abrog
neutral
activ
avian
pandem
viral
strain
less
glycosyl
ha
strain
evolv
year
human
popul
therefor
want
determin
whether
crosslink
construct
would
increas
activ
less
glycosyl
viral
strain
purpos
use
strain
deriv
strain
use
studi
lack
key
oligomannos
glycan
attach
tip
viral
ha
test
effect
hncrd
alon
crosslink
proteinhrp
mab
isotyp
control
ha
activ
strain
shown
tabl
proteinhrp
mab
caus
consider
increas
activ
strain
strain
less
sensit
inhibit
crosslink
hncrd
prepar
caus
ha
inhibit
activ
significantli
increas
proteinhrp
conglutinin
ncrd
proteinhrp
caus
significantli
greater
inhibit
spd
ncrd
proteinhrp
p
proteinhrp
caus
significantli
greater
inhibit
ncrd
parent
strain
howev
combin
either
mab
proteinhrp
inhibitori
nanomolar
concentr
contrast
even
crosslink
gml
hncrd
need
inhibit
strain
isotyp
control
antibodi
caus
increas
activ
either
hncrd
studi
establish
abil
mab
increas
antivir
activ
either
human
rat
spd
ncrd
depend
fc
domain
requir
bival
use
f
ab
fragment
pro
mab
alon
f
ab
fig
effect
mab
alon
fab
fragment
mab
abil
bind
iav
inhibit
ha
activ
iav
b
c
neutral
iav
bind
iav
significantli
increas
assess
elisa
ngml
use
n
either
mab
ad
b
similarli
mab
significantli
increas
abil
inhibit
ha
activ
iav
n
p
note
measur
hainhibitori
activ
unlik
wildtyp
ncrd
c
addit
f
ab
fragment
mab
significantli
increas
hainhibit
activ
wherea
f
ab
fragment
significantli
reduc
n
p
similarli
intact
mab
significantli
increas
viral
neutral
activ
wherea
f
ab
fragment
strongli
reduc
n
p
vide
minim
model
crosslink
suggest
format
hexam
ie
trimer
togeth
suffici
enhanc
viral
bind
reach
similar
conclus
recent
studi
involv
modifi
form
rat
spd
lack
one
half
collagen
domain
molecul
call
minispd
increas
antivir
opson
activ
compar
wildtyp
rat
spd
electron
microscopi
form
dodecam
trimer
ncrd
head
adjac
rais
possibl
hexamer
bind
surfac
may
easili
gener
form
spd
util
proteinhrp
altern
mean
crosslink
ncrd
proteinhrp
conjug
present
protein
function
multival
manner
wherea
free
protein
proteinbiotin
result
show
format
multimer
array
hncrd
rncrd
import
gener
antivir
activ
sinc
complex
form
proteinhrp
result
increas
viral
bind
neutral
hainhibit
activ
compar
ncrd
proteinhrp
alon
monomer
protein
prepar
effect
engag
fc
receptor
neutrophil
monocyt
variou
antibodyantigen
complex
increas
phagocytosi
antigen
cell
activ
assess
respiratori
burst
activ
previous
shown
complex
antivir
antibodi
iav
particl
result
mark
potenti
iavinduc
neutrophil
respiratori
burst
respons
similarli
tacken
et
al
report
similar
result
use
mab
direct
iav
bispecif
protein
contain
hncrd
coupl
f
ab
fragment
direct
neutrophil
fc
receptor
abl
simultan
bind
fc
receptor
viral
particl
ncrd
domain
also
shown
preincub
iav
fulllength
spd
dodecam
markedli
potenti
viral
uptak
neutrophil
virusinduc
respiratori
burst
respons
specul
effect
result
larg
part
spdmediat
viral
aggreg
anoth
possibl
ntermin
collagen
domain
spd
collectin
engag
specif
receptor
phagocyt
trigger
phagocytosi
increas
cellular
activ
instanc
gardai
et
al
shown
receptor
import
mediat
macrophag
phagocytosi
activ
respons
complex
spd
lipopolysaccharid
apoptot
cell
fragment
use
fab
fragment
proteinhrp
assess
role
fc
receptor
abil
mab
confer
opson
activ
human
spd
ncrd
wildtyp
hncrd
opson
activ
similar
prior
find
fulllength
trimer
spd
caus
viral
aggreg
increas
neutrophil
uptak
respiratori
burst
respons
iav
f
ab
essenti
equival
intact
mab
increas
neutral
hainhibit
activ
hncrd
less
activ
mab
increas
opson
activ
hncrd
specif
crosslink
hncrd
f
ab
modestli
increas
uptak
iav
neutrophil
result
shown
amount
ncrd
gml
need
inhibit
hemagglutinin
unit
indic
viral
strain
mean
sem
experi
amount
mab
isotyp
control
use
gml
signific
reduct
concentr
need
inhibit
proteinhrp
mab
compar
ncrd
alon
valu
approxim
gml
variabl
inhibit
concentr
limit
detect
assay
f
ab
howev
intact
mab
consider
activ
regard
combin
f
ab
fragment
hncrd
also
enhanc
neutrophil
respiratori
burst
respons
compar
iav
alon
impli
fc
domain
mab
engag
fc
receptor
neutrophil
particip
enhanc
viral
uptak
h
gener
also
shown
crosslink
human
spd
ncrd
result
increas
abil
promot
uptak
macrophagelik
cell
line
raw
fc
domain
mab
appear
contribut
enhanc
uptak
raw
cell
f
ab
intact
mab
similar
effect
may
differ
fc
receptor
human
neutrophil
murin
raw
cell
involv
effect
case
noteworthi
crosslink
hncrd
also
increas
uptak
macrophagelik
cell
result
suggest
receptor
ntermin
domain
spd
critic
increas
uptak
iav
spd
ie
f
ab
hncrd
increas
uptak
also
show
crosslink
spd
ncrd
proteinhrp
complex
allow
ncrd
induc
viral
aggreg
increas
neutrophil
raw
cell
uptak
iav
find
suggest
ntermin
domain
spd
requir
potenti
viral
uptak
phagocyt
long
viral
aggreg
occur
previous
shown
chimer
molecul
compos
ntermin
collagen
domain
spd
ncrd
either
mbl
conglutinin
increas
antivir
activ
compar
wildtyp
spd
addit
ncrd
prepar
increas
activ
compar
similar
prepar
spd
find
suggest
ncrd
serum
collectin
increas
intrins
antivir
activ
compar
spd
hncrd
sinc
wildtyp
ncrd
measur
activ
absenc
crosslink
use
proteinhrp
complex
potenti
antivir
activ
set
wildtyp
ncrd
prepar
similar
manner
contain
protein
bind
site
use
method
establish
hierarchi
activ
wildtyp
ncrd
follow
conglutinin
spd
mbl
interest
mbl
ncrd
roughli
equival
activ
rat
mous
spd
ncrd
previous
shown
intrins
antivir
activ
hncrd
greatli
increas
specif
mutat
residu
surround
lectinbind
site
ncrd
mutat
increas
abil
hncrd
bind
highmannos
glycan
type
found
viral
ha
recent
human
strain
demonstr
neutral
activ
strongli
potenti
crosslink
mab
combin
effect
mutat
crosslink
result
inhibit
iav
concentr
ngml
activ
crosslink
proteinhrp
also
notabl
sinc
greater
activ
wildtyp
collectin
treat
similar
manner
result
support
concept
combin
two
method
increas
activ
ncrd
ie
mutagenesi
bind
region
crosslink
trimer
addit
synergist
effect
interest
crosslink
either
mab
proteinhrp
also
caus
mark
increas
activ
hypoglycosyl
strain
iav
suggest
combin
strategi
mutagenesi
ncrd
crosslink
could
increas
activ
pandem
viral
strain
diminish
envelop
protein
glycosyl
find
potenti
relev
therapeut
ncrd
rel
easi
produc
larg
quantiti
addit
use
collectin
without
includ
collagen
domain
could
advantag
collagen
domain
associ
potenti
proinflammatori
effect
spd
use
proteinhrp
complex
crosslink
ncrd
valuabl
tool
evalu
mechan
activ
spd
potenti
therapi
contrast
use
mab
fragment
crosslink
ncrd
also
conceiv
clinic
applic
mani
mab
use
effect
treatment
infecti
inflammatori
diseas
cancer
instanc
palivizumab
mab
direct
respiratori
syncyti
viru
fusion
protein
effect
prophylaxi
sever
infect
impli
mab
achiev
signific
level
lung
inhibit
respiratori
viral
replic
furthermor
f
ab
f
ab
fragment
also
use
treatment
certolizumab
f
ab
fragment
mab
direct
tumor
necrosi
factor
alpha
signific
therapeut
benefit
crohn
diseas
case
conjug
f
ab
fragment
polyethylen
glycol
use
prolong
serum
halflif
anim
model
f
ab
fragment
direct
sever
acut
respiratori
syndrom
coronaviru
highli
pathogen
iav
show
therapeut
benefit
indic
antibodi
fragment
achiev
meaning
level
respiratori
tract
awar
therapi
use
mab
fragment
antibodi
potenti
activ
endogen
host
defens
molecul
combin
therapeut
administ
inhibitor
like
ncrd
test
approach
mous
model
seem
plausibl
specif
advantag
use
f
ab
fragment
crosslink
ncrd
possibl
endogen
spd
lack
fc
domain
fragment
provok
complement
activ
antibodydepend
cellular
cytotox
respiratori
burst
activ
neutrophil
evid
reactiv
oxygen
nitrogen
speci
harm
context
sever
iav
infect
could
advantag
avoid
trigger
respons
also
specif
interest
crosslink
ncrd
mbl
result
increas
antivir
activ
without
use
ntermin
collagen
domain
could
therapeut
interest
sinc
ntermin
collagen
domain
mbl
mediat
complement
activ
could
deleteri
set
